evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

28 questions · 28 findings · 9 reviews · Haematology

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 6 · 21.4%GRADE not reported 1 · 3.6%Very low 6 · 21.4%Low 12 · 42.9%Moderate 3 · 10.7%High 0 · 0%

Summary of findings table ‐ Convalescent plasma vs placebo or usual care

Grades 3 and 4 adverse events · individuals with moderate to severe disease

Summary of findings table ‐ Convalescent plasma showed no clear difference in grades 3 and 4 adverse events compared with placebo or standard care alone (low certainty).

1 finding from 1 review

Summary of findings table ‐ Convalescent plasma vs placebo or usual care

Serious adverse events ‐ total · individuals with moderate to severe disease

Summary of findings table ‐ Convalescent plasma showed no clear difference in serious adverse events ‐ total compared with placebo or standard care alone (moderate certainty).

1 finding from 1 review

Intervention not reported

Serious adverse events at longest · hospitalised adults with COVID‐19 (moderate to severe disease)

The intervention showed no clear difference in serious adverse events at longest (low certainty).

1 finding from 1 review

RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies (EpAbs) vs saline placebo

Serious adverse events (by day 28) · individuals with moderate or severe COVID‐19

RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in serious adverse events (by day 28) compared with saline placebo (low certainty).

1 finding from 1 review

Intervention not reported

Adverse events during study treatment · hospitalised adults with COVID‐19 (moderate to severe disease)

The review found no eligible studies for this question.

1 finding from 1 review

Remdesivir and standard care vs placebo or usual care

Serious adverse events at up to day 28 · hospitalised individuals with COVID‐19 (moderate to severe disease)

Remdesivir and standard care showed no clear difference in serious adverse events at up to day 28 compared with standard care (plus/minus placebo) (low certainty).

1 finding from 1 review

RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies (EpAbs) vs saline placebo

Adverse events: all grades · individuals with moderate or severe COVID‐19

RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… showed no clear difference in adverse events of any grade (by day 28) compared with saline placebo (low certainty).

1 finding from 1 review

Remdesivir and standard care vs placebo or usual care

Adverse events: all grades · hospitalised individuals with COVID‐19 (moderate to severe disease)

Remdesivir and standard care showed no clear difference in adverse events (any grade) at up to day 28 compared with standard care (plus/minus placebo) (low certainty).

1 finding from 1 review